Navigation Links
ClinStar to Present on Conducting Clinical Trials in Russia
Date:7/21/2011

SAN FRANCISCO, July 21, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that President and CEO David Passov will speak at Marcus Evans 6th Annual Clinical Research in Emerging Countries conference July 28-29 in Miami, FL.   

(Logo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO)

The paradigm of traditional drug development is shifting as more and more biopharmaceutical organizations look to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment. During his presentation scheduled for Thursday, July 28 at 10:30 a.m., Mr. Passov will address the perceptions of emerging markets; consider the benefits of conducting clinical trials in Russia compared to other emerging countries; and explore how best to navigate the new clinical trial regulations in order to optimize clinical trial performance. Mr. Passov will also chair the first day of this year's conference.

The Marcus Evans Clinical Research in Emerging Countries conference, now in its 6th year, will offer a half day workshop on July 27 followed by two days of sessions led by pharmaceutical and biotechnology industry leaders. Marcus Evans Emerging Countries conference series is aimed at equipping industry professionals with necessary knowledge on critical globalization issues such as regulatory and legal compliance, training of personnel, overcoming cultural barriers, and clinical outsourcing opportunities.  

About ClinStar, LLC

ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.


'/>"/>
SOURCE ClinStar, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ClinStar, LLC Establishes New Office on the US East Coast
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... ... President and CEO of EMED, today signed a multifaceted agreement which will allow ... the Northern Caribbean University Department of Natural and Applied Sciences, Allied Health and ...
(Date:4/29/2016)... ... 30, 2016 , ... Mercy College is expanding its Graduate Business Programs to ... expanding due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe ...
(Date:4/29/2016)... ... 29, 2016 , ... Our bodies are bombarded daily by environmental and lifestyle ... these stressors is to adopt a more healthful diet, but too many people think ... certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
Breaking Medicine News(10 mins):